Male breast cancer (MBC) is uncommon, accounting for roughly 1% of all male malignancies and 1% of all breast cancers (BCs) worldwide1–4. MBC accounts for just under 0.2% of cancer-related mortality in men. Due to the low incidence of MBC, BC literature, research, clinical trials, and the advancement of novel treatments primarily focus on female BC. Male and female BC have been described to have distinct molecular and clinicopathologic characteristics5–9. According to statistical projections, ~2670 novel incidences of BC were anticipated to be detected among the male population in the United States during the year 2019, with a projected 500 fatalities resulting from this disease10. The incidence rate of BC in males is ~1 in 1000, whereas in females, it is roughly 1 in 8, resulting in a significantly higher risk for women. The overall BC rates in men and women increase progressively with age. Nevertheless, the mean age of initial diagnosis of BC in men is comparatively higher, with an average of 67 years, in contrast to women diagnosed at an average age of 62 years11. Significant gaps in understanding exist regarding the most effective approach to managing BC in male patients. Thus far, the methodologies employed in managing MBC have been primarily derived from studies on female BC patients12. Clinical trials that are currently in progress or have been planned, with an emphasis on MBC treatment, can influence the standard of care in the future. However, these trials are still in progress and will require several years. The current guideline issued by the American Society of Clinical Oncology (ASCO) provides recommendations about various crucial facets of MBC management13. In this correspondence article, we discuss the background, risk factors, and potential future treatments for treating MBC. We have tried to shed light on the importance of MBC and why it calls for a detailed discussion and research on this topic.